This Article Full Text (PDF) All Versions of this Article: 1352458508097468v1 15/2/272    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ali, E. Articles by Khoury, S. Search for Related Content PubMed PubMed Citation Articles by Ali, E. Articles by Khoury, S. Social Bookmarking                         What's this?

Daclizumab in treatment of multiple sclerosis patients

Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; Correspondence to: EN Ali, MD, Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. Email: eman_c5{at}yahoo.com

BC Healy

Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; Correspondence to: EN Ali, MD, Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. Email: eman_c5{at}yahoo.com

LA Stazzone

Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; Correspondence to: EN Ali, MD, Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. Email: eman_c5{at}yahoo.com

BA Brown

Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; Correspondence to: EN Ali, MD, Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. Email: eman_c5{at}yahoo.com

HL Weiner

Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; Correspondence to: EN Ali, MD, Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. Email: eman_c5{at}yahoo.com

SJ Khoury

Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; Correspondence to: EN Ali, MD, Partners MS Center, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts, USA. Email: eman_c5{at}yahoo.com

Background

Daclizumab is a humanized monoclonal antibody (mAb) that blocks the interleukin-2 receptor alpha subunit (IL-2R-alpha chain; CD25) expressed on activated T cells leading to the inhibition of T-cell expansion, thus strongly reduces brain inflammation in patients with multiple sclerosis (MS). Another mechanism is significant expansion of CD56 (bright) natural killer (NK) cells that in turn inhibit T-cell survival.

Objective

At the Partners MS center, we have been using Daclizumab in an open-label fashion in patients who fail first line therapy or non-standard immunosuppressive treatment. Our aim was to assess its safety and tolerability in our patient population.

Key Words: all clinical trials • daclizumab • disease modifying therapies • multiple sclerosis

This version was published on February 1, 2009

Multiple Sclerosis, Vol. 15, No. 2, 272-274 (2009)
DOI: 10.1177/1352458508097468


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?